ASX:CSL – The Australian pharma giant on Trump’s tariff hit list can ride out the storm

Australian pharmaceutical giant CSL is on tariff watch after US President Donald Trump threatened to slug pharmaceutical imports into the US with a 200 per cent impost, two months after asking the US government to carefully consider the consequences of the measure.CSL is an $117 billion ASX…


Click here to view the original article.